Reinforcing its commitment to pioneering advanced cancer care, Sarvodaya Hospital, Faridabad, Delhi NCR is proud to announce that it has become the first Theranostics and Nuclear Medicine center in India to offer Terbium-161 PSMA therapy for prostate cancer treatment. This marks a significant milestone, positioning Sarvodaya Hospital as a leader in providing comprehensive cancer care.

为进一步彰显其对开创先进癌症治疗的承诺，法里达巴德萨罗瓦迪亚医院（位于德里国家首都辖区）自豪地宣布，它已成为印度首家提供铽-161 PSMA疗法治疗前列腺癌的治疗诊断学与核医学中心。这一里程碑标志着萨罗瓦迪亚医院在提供全面癌症治疗方面确立了领导地位。

Furthermore, this cutting-edge nuclear therapy represents a notable step in cancer treatment, offering new hope to patients with advanced metastatic castration resistant / hormone refractory prostate cancer..

此外，这种尖端的核疗法代表了癌症治疗的一个重要进步，为患有晚期转移性去势抵抗性/激素难治性前列腺癌的患者提供了新的希望。

Further strengthening its role at the forefront of cancer innovation, Sarvodaya Cancer Institute has also introduced CAR-T Cell therapy, one of the most advanced treatments for blood cancers like leukemia, lymphoma, and multiple myeloma. With this, the hospital now offers complete cancer care, from diagnosis to advanced treatment, all under one roof..

进一步加强其在癌症创新前沿的角色，萨罗瓦达癌症研究所还引入了CAR-T细胞疗法，这是针对白血病、淋巴瘤和多发性骨髓瘤等血液癌最先进的治疗方法之一。通过这项技术，该医院现在提供从诊断到高级治疗的一站式全面癌症护理。

Dr. Swagat Dash, HOD & Senior Consultant – Nuclear Medicine

斯瓦加特·达什博士，核医学科主任及高级顾问

,

，

Sarvodaya Cancer Institute, Sarvodaya Hospital

萨罗瓦达癌症研究所，萨罗瓦达医院

,

，

Faridabad

法里达巴德

, leading the initiative stated, “The introduction of this groundbreaking therapy in India will bring renewed hope to patients battling with advanced prostate cancer. This marks a significant step in precision oncology, and the team at Sarvodaya remains committed to delivering advanced and cutting-edge cancer care.”.

，该倡议的领导者表示：“这种开创性疗法在印度的引入将为晚期前列腺癌患者带来新的希望。这标志着精准肿瘤学迈出了重要一步，Sarvodaya 团队将继续致力于提供先进和前沿的癌症治疗。”

Dr. Dinesh Pendharkar, Director, Sarvodaya Cancer Institute, Sarvodaya Hospital

迪内什·彭达卡尔博士，萨尔沃达亚癌症研究所主任，萨尔沃达亚医院

,

，

Faridabad

法里达巴德

, said “At Sarvodaya Hospital, we remain committed to treat patients through evidence-based techniques as well as to improve outcomes for the patients. We are honored to pioneer this revolution in India because terbium-161 PSMA therapy represents a novel approach to treat advanced prostate cancer. We are shifting the landscape in terms of what complete cancer care means with CAR-T Cell therapy as well as Theranostics.”.

，他说：“在萨罗瓦达医院，我们始终坚持通过基于证据的技术来治疗患者，并且致力于改善患者的治疗效果。我们很荣幸能够在印度引领这场革命，因为铽-161 PSMA疗法代表了一种治疗晚期前列腺癌的新方法。我们正在通过CAR-T细胞疗法和治疗诊断学改变完全癌症护理的定义。”